223 related articles for article (PubMed ID: 28048946)
1. Intravitreal Anti-Vascular Endothelial Growth Factor Drugs for Retinal Angiomatous Proliferation in Real-Life Practice.
Parodi MB; Donati S; Semeraro F; Danzi P; Introini U; Viola F; Bottoni F; Pucci V; Musig A; Pece A; Azzolini C
J Ocul Pharmacol Ther; 2017 Mar; 33(2):123-127. PubMed ID: 28048946
[TBL] [Abstract][Full Text] [Related]
2. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
Korean J Ophthalmol; 2017 Jun; 31(3):240-248. PubMed ID: 28471100
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Daniel E; Shaffer J; Ying GS; Grunwald JE; Martin DF; Jaffe GJ; Maguire MG;
Ophthalmology; 2016 Mar; 123(3):609-16. PubMed ID: 26681392
[TBL] [Abstract][Full Text] [Related]
5. [Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Lommatzsch A; Heimes B; Gutfleisch M; Spital G; Dietzel M; Pauleikhoff D
Ophthalmologe; 2011 Mar; 108(3):244-51. PubMed ID: 20571805
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
7. CHOROIDAL THICKNESS CHANGE AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN RETINAL ANGIOMATOUS PROLIFERATION AND ITS RECURRENCE.
Kim YK; Park SJ; Woo SJ; Park KH
Retina; 2016 Aug; 36(8):1516-26. PubMed ID: 26735564
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series.
Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F
Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164
[TBL] [Abstract][Full Text] [Related]
9. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NAIVE IDIOPATHIC CHOROIDAL NEOVASCULARIZATION: A Comparative Study.
Sudhalkar A; Yogi R; Chhablani J
Retina; 2015 Jul; 35(7):1368-74. PubMed ID: 25830696
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration.
Giansanti F; Bacherini D; Giacomelli G; Virgili G; Finocchio L; Fiore T; Vannozzi L; Menchini U
Eur J Ophthalmol; 2014; 24(3):402-8. PubMed ID: 24242217
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment.
Giacomelli G; Finocchio L; Biagini I; Sodi A; Murro V; Introini U; Varano M; Bandello F; Menchini U
Ophthalmologica; 2017; 238(1-2):44-51. PubMed ID: 28641290
[TBL] [Abstract][Full Text] [Related]
13. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.
Hufendiek K; Hufendiek K; Panagakis G; Helbig H; Gamulescu MA
Int Ophthalmol; 2012 Jun; 32(3):259-68. PubMed ID: 22527448
[TBL] [Abstract][Full Text] [Related]
14. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
15. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.
Park YG; Roh YJ
BMC Ophthalmol; 2015 Dec; 15():182. PubMed ID: 26691185
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.
Chevreaud O; Oubraham H; Cohen SY; Jung C; Blanco-Garavito R; Gherdaoui F; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):743-751. PubMed ID: 27913869
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
18. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
19. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]